 |
|
|
|
 |
|
|
| Article 1 to 10 out of 12 concerning Bavarian Nordic A/S
|
-
Bavarian Nordic: Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
(09 Oct 2008)
125 Patient, Prospective Randomized Placebo-Controlled Phase II Study
Bavarian Nordic has now evaluated the mature phase II data from the therapeutic prostate cancer vaccine candidate PROSTVAC(TM) that had been obtained as part of the recently entered partnership with the National Cancer Institute (NCI) in the US.The ...
-
Bavarian Nordic announces partnership with National Cancer Institute in the US and obtains rights to a new vaccine candidate
(14 Aug 2008)
Bavarian Nordic's US subsidiary, BN ImmunoTherapeutics has entered into a scientific partnership with the National Cancer Institute (NCI) in the United States. Under the Cooperative Research and Development Agreement (CRADA) the NCI and Bavarian ...
-
Bavarian Nordic enters clinical trials with prostate cancer vaccine
(06 Jun 2008)
Bavarian Nordic's subsidiary, BN ImmunoTherapeutics has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.A Phase I/II safety and tolerability study in 18 male patients with non-metastatic as well ...
-
Bavarian Nordic enters clinical trials with HIV multiantigen vaccine
(28 May 2008)
Bavarian Nordic has initiated Phase I/II clinical study with its HIV vaccine candidate: MVA-BN® HIV multiantigen. A Phase I/II safety and immunogenicity study in 15 HIV-infected patients (CD4 counts > 350 ul/ml) has begun enrolment in the United ...
-
Post-exposure vaccination with IMVAMUNE protects against lethal poxvirus infection
(14 Apr 2008)
In studies with Bavarian Nordic's new and innovative third-generation smallpox vaccine, IMVAMUNE®, scientists from Bavarian Nordic have for the first time demonstrated a therapeutic effect of a smallpox vaccine, days after infection. With the ...
-
Bavarian Nordic Receives USD 25 Million Milestone Payment from the U.S. Government for Fulfilling Contract Milestones
(03 Dec 2007)
Bavarian Nordic has received permission from the U.S. authorities to invoice a milestone payment of USD 25 million as allowed under the RFP-3 contract to manufacture and deliver 20 million doses of the company's, IMVAMUNE® smallpox vaccine. The ...
-
Bavarian Nordic A/S reports positive data from first EUA enabling study with IMVAMUNE smallpox vaccine
(30 Nov 2007)
Bavarian Nordic reports the successful completion of a large, placebo-controlled Phase II trial in 745 healthy subjects who received either one or two doses of IMVAMUNE® third-generation smallpox vaccine. The results of this study are seen as the ...
-
U.S. government extends RFP-2 contract with Bavarian Nordic
(05 Oct 2007)
The U.S. government has extended the RFP-2 contract that was awarded to Bavarian Nordic in 2004. Within the scope of the extension, Bavarian Nordic will initiate a larger Phase II study with IMVAMUNE® in people diagnosed with atopic dermatitis. The ...
-
Pharmexa and Bavarian Nordic initiate new NIH funded Phase I trial of HIV vaccines in combination
(03 May 2007)
Pharmexa-Epimmune and Bavarian Nordic announced the initiation of a Phase I trial testing two HIV vaccines EP1233 and MVA-BN Polytope in combination. The clinical trial will be conducted by the HIV Vaccine Trials Network (HVTN) which is supported ...
-
Pharmexa and BN ImmunoTherapeutics enter license agreement
(07 Mar 2005)
Pharmexa has entered into an agreement with BN ImmunoTherapeutics, whereby BN ImmunoTherapeutics obtains a worldwide non-exclusive license to formulate our HER-2 DNA AutoVac(TM) therapeutic vaccine technology against breast cancer in their MVA-BN ...
Additional information
Bavarian Nordic A/S
Kvistgård, Denmark
Company
|
|
|
|
|
|
Top
